-
1 week ago | 
healio.com | Raj Chovatiya |Erin Michael
In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American Academy of Dermatology Annual Meeting. The study assessed the use of ESK-001 (Alumis), an oral tyrosine kinase 2 inhibitor, among patients with moderate-to-severe plaque psoriasis.
-
1 week ago | 
healio.com | Raj Chovatiya |Erin Michael |Carol L. DiBerardino
In this video, Raj Chovatiya, MD, PhD, discusses updates on oral therapies in psoriasis from the American Academy of Dermatology Annual Meeting. “We saw updates largely in the oral therapeutic realm, even more so than the biologic therapeutic realm,” Chovatiya, who is a clinical associate professor for Chicago Medical School at Rosalind Franklin University and assistant clinical professor at George Washington University School of Health Sciences, said.
-
2 weeks ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“Chronic hand eczema can be a tricky diagnosis and a tricky thing to treat, in part because we don't always agree on what the diagnosis is. As long as you've had multiple bouts of eczema on your hands in one year, or a particular symptom of patterns that have been going on for at least 3 months, you really fit the bill for chronic hand eczema,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
2 weeks ago | 
ajmc.com | Cameron Santoro |Raj Chovatiya
Raj Chovatiya, MD, PhD, MSCI, clinical associate professor of medicine at Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology/Immunology Research, emphasizes promising atopic dermatitis research aiming to identify patient subgroups for targeted treatments using biomarkers and clinical traits.
-
1 month ago | 
patientcareonline.com | Raj Chovatiya |Grace Halsey
Raj Chovatiya, MD, PhD, MSCI, clinical associate professor of medicine, Rosalind Franklin University Chicago Medical School, in Chicago, IL, made the comment that "symptoms never lie" in a conversation about recognizing and treating skin conditions in primary care and particularly in patients with skin of color. "Even if you don't know morphologically exactly what you're seeing, asking some questions about the skin, 'Is it itchy? Is it painful?
-
1 month ago | 
patientcareonline.com | Raj Chovatiya |Grace Halsey
Clinical trial data on efficacy of the medications studied and approved for dermatologic disorders including atopic dermatitis, psoriasis, hidradenitis suppurativa, and others suggest no difference across skin of different Fitzpatrick phototypes, Raj Chovatiya, MD, PhD, MSCI, told Patient Care©in a recent interview. "The real world data seem to suggest that, too," he added.
-
1 month ago | 
patientcareonline.com | Raj Chovatiya |Grace Halsey
"The exposome is everything with atopic dermatitis (AD)," Raj Chovatiya, MD, PhD, MSCI, clinical associate professor of medicine at the Rosalind Franklin University Chicago Medical School, in Chicago, IL, said in an interview with Patient Care.©The statement was in response to a question about a potential differential impact of internal and external factors on both the manifestation and burden of AD in people with skin of color (SoC).
-
1 month ago | 
patientcareonline.com | Raj Chovatiya |Grace Halsey
The concentration of melanin in skin, responsible for perceived tone and Fitzpatrick phototype, certainly affects response to solar radiation and so contributes to differences in risk for skin cancer, Raj Chovatiya, MD, PhD, MSCI, told Patient Care Online© during an interview at the American Academy of Dermatology Annual Meeting, March 7-11, in Orlando, FL. "For many of these other diseases that are largely immune mediated in nature, that's a little trickier," he continued.
-
1 month ago | 
patientcareonline.com | Raj Chovatiya |Grace Halsey
"I'd say a better way to think about it is understanding the diversity that underlies a lot of dermatologic disease, both in terms of clinical manifestations and how that affects treatment-related and/or quality-of-lif- related outcomes."The area of skin of color as a focus in research of dermatologic disorders has seen renewed emphasis in the past several years, according to Raj Chovatiya, MD, PhD, MSCI.
-
1 month ago | 
dermatologytimes.com | Kaitlyn Bader |Raj Chovatiya
“Many of the disparities that we see with disease identification, epidemiology, quality of life impairment, and even burden, oftentimes have to do with social and structural factors. I tried to address these in the second half of my lecture by focusing in on some interesting things that have been happening in the space for each disease state,” said Raj Chovatiya, MD, PhD, MSCI, in an interview at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
